BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth Londoner tells Proactive the Connecticut-based biotech is enrolling patients for its Phase 2 trial of merimepodib, its drug candidate for the treatment of the coronavirus.
Londoner says BioSig, along with its subsidiary ViralClear Pharmaceuticals Inc, is enrolling patients at trial sites in Austin, Texas; Rochester, Minnesota; Jacksonville, Florida; and Scottsdale, Arizona, expecting to report results later this summer.
Price: 3.41 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of BioSig Technologies, Inc. named herein, including the promotion by the Company of BioSig Technologies, Inc. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth Londoner tells Proactive the group's subsidiary ViralClear Pharmaceuticals, Inc is teaming up with Sorrento Therapeutics, Inc. (NASDAQ: SRNE) to advance the fight against the coronavirus. Londoner says the two biotechs will look at the effective...
Prev article
